Back to results
US 2013/0095100 A1Published application
Heterocyclic kinase inhibitors
AssigneeConcert Pharmaceuticals, Inc.
InventorRoger D. Tung
Life of this patent
Estimating the term…
Abstract
This invention relates to novel 2-{6-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-2-methyl-pyrimidin-4-ylamino}-thiazole-5-carboxylic acid (2-chloro-6-methyl-phenyl)-amide derivatives, and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by the inhibition of kinases including Src-kinase and Bcr-Abl kinase.
Claims12
-6. (canceled)
A compound of Formula I:
- or a salt thereof;
- wherein:
- each W is independently selected from hydrogen or deuterium;
- each Y is independently selected from hydrogen or deuterium;
- each Z is independently selected from hydrogen or deuterium, and the compound is selected from any one of the compounds in the table below:
- Cmpd
- Each Y1
- Each Y2
- Each Z
- Each W1
- Each W2
- 102
- H
- D
- D
- H
- H
- 104
- D
- D
- H
- D
- H
- 105
- D
- D
- H
- H
- D
- 106
- D
- H
- D
- D
- H
- 107
- D
- H
- D
- H
- D
- 108
- H
- D
- D
- D
- H
- 109
- H
- D
- D
- H
- D
- 110
- D
- D
- D
- D
- H
- 111
- D
- D
- D
- H
- D
- 112
- D
- D
- H
- D
- D
- 113
- D
- H
- D
- D
- D
- 114
- H
- D
- D
- D
- D
- 116
- D
- H
- H
- H
- H
- 119
- H
- H
- D
- D
- D
92 more elements
Dependencies are inferred from the claim text.